5 completed. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
Follow Latent Tuberculosis Infection: new trials by email Literature Review of Latent Tuberculosis Infection trials Research Report on Latent Tuberculosis Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above Recombinant Mycobacterium Tuberculosis Fusion Protein, Purified Protein Derivative of Tuberculin - Latent Tuberculosis Infection | Phase 3 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 780 | 2023-08-03 | 2026-04-30 |
| Risk of SDRs Under 3HP and 1HP Regimen for LTBI isoniazid and rifapentine - Latent Tuberculosis Infection | Phase 3 | Completed | National Taiwan University Hospital | 490 | 2019-09-24 | 2023-12-26 |
| Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine - Latent Tuberculosis Infection | Phase 3 | Completed | Centers for Disease Control and Prevention | 1002 | 2012-09-01 | 2025-03-13 |
| Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9) Isoniazid, Rifampin - Latent Tuberculosis Infection | Phase 3 | Completed | McGill University | 844 | 2011-08-01 | 2017-12-19 |
| Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness Isoniazid, Rifampin - Latent Tuberculosis Infection | Phase 3 | Completed | McGill University | 6031 | 2009-08-01 | 2017-12-19 |
Latent Tuberculosis (5) · Tuberculosis (2)
Actinomycetales Infections (5) · Bacterial Infections (5) · Bacterial Infections and Mycoses (5) · Gram-Positive Bacterial Infections (5) · Infections (5) · Latent Infection (5) · Mycobacterium Infections (5) · Tuberculosis (3)
Isoniazid (4) · Rifampin (2) · rifapentine (2) · Tuberculin (1)
McGill University (2) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1) · Centers for Disease Control and Prevention (1) · National Taiwan University Hospital (1)
Australia (2) · Benin (2) · Brazil (2) · Canada (2) · China (2) · Ghana (2) · Guinea (2) · Indonesia (2) · Saudi Arabia (1) · South Africa (1) · South Korea (1) · Spain (1) · Taiwan (1) · United States (1)
Andrey S Borisov, MD, MPH (1) · Dick Menzies, MD (1) · Dick Menzies, MD, MSc (1) · Jann-Yuan Wang, MD, PhD (1) · Robert Belknap, MD (1) · Shuihua Lu, bachelor (1)
PMID 31866327, PMID 32539440, PMID 32785709, PMID 36949623, PMID 20627913, PMID 25404412, PMID 29114781, PMID 29393655, PMID 30067928, PMID 30067931, PMID 36815322, PMID 38996972